JP5586094B2 - Qt延長に対する素因を予測する方法 - Google Patents
Qt延長に対する素因を予測する方法 Download PDFInfo
- Publication number
- JP5586094B2 JP5586094B2 JP2010501271A JP2010501271A JP5586094B2 JP 5586094 B2 JP5586094 B2 JP 5586094B2 JP 2010501271 A JP2010501271 A JP 2010501271A JP 2010501271 A JP2010501271 A JP 2010501271A JP 5586094 B2 JP5586094 B2 JP 5586094B2
- Authority
- JP
- Japan
- Prior art keywords
- interval
- individual
- cerkl
- predisposition
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は、参照により本明細書に組み込まれる、2007年3月29日出願の同時係属中の米国特許仮出願第60/908,734号の利益を主張する。
2008年3月28日に作成された「VAND−0042−PCT_sequence_listings.txt」という名称の4.1MBの電子ファイルに含まれる配列表が、参照により本明細書に組み込まれる。
1.技術分野
本発明は概して、個体のQT延長に対する素因を予測する方法に関し、より具体的には、このような素因を個体のセラミドキナーゼ様(CERKL)遺伝子の配列に基づいて予測する方法に関する。
心電図のQT間隔(Q波の始まりからT波の終わりまでの時間)の延長は、QT延長症候群(LQTS)と称される。LQTSは、遺伝的要素を含む可能性がある。LQTSの一部の患者において、QT延長は、慢性状態であり得る。人によっては、LQTSは、QT間隔を延長する医薬品有効成分の投与によって誘発されることがある。
本発明は、セラミドキナーゼ様(CERKL)遺伝子における遺伝子多型性とQT間隔の延長に対する素因との間の関連を説明し、そのような素因を診断し、QT間隔を延長する化合物を、そのような素因を有する個体に投与する関連方法を提供する。
上に示したように、本発明は、個体、例えば、ヒト対象のQT延長に対する素因を、個体のセラミドキナーゼ様(CERKL)遺伝子の配列に基づいて予測する方法を提供する。
Claims (7)
- 非ヒト動物のセラミドキナーゼ様(CERKL)遺伝子の発現産物のレベルを測定するステップであって、発現産物が、rs895901、rs1441162、rs993650、rs993648、rs16867450、rs16867452、及びrs6433927からなる群から選択された、少なくとも1つの一塩基多型(SNP)座位から転写又は翻訳された配列を含むステップと、
ある量の化合物を非ヒト動物に投与するステップと、
非ヒト動物のCERKL遺伝子の発現産物のレベルを再測定するステップと、
化合物が非ヒト動物のQT間隔を延長し得るか否かを、非ヒト動物のCERKL遺伝子の発現産物の測定の差に基づいて決定するステップと
を含む、化合物が非ヒト動物におけるQT間隔を延長し得るか否かを決定する方法。 - 発現産物が、mRNA、ペプチド、及びタンパク質からなる群から選択された、少なくとも1つの発現産物を含む、請求項1に記載の方法。
- QT間隔の延長に対する素因に関連するセラミドキナーゼ様(CERKL)遺伝子型を有する第1の非ヒト動物、及びQT間隔の延長に対する素因に関連しないCERKL遺伝子型を有する第2の非ヒト動物を含む、複数の非ヒト動物の各々のQT間隔を測定するステップと、
複数の非ヒト動物の各々にある量の化合物を投与するステップと、
少なくとも第1の非ヒト動物のQT間隔を再測定するステップと、
再測定されたQT間隔が測定されたQT間隔を超える場合に、化合物が個体におけるQT間隔を延長し得ると決定するステップと
を含む、化合物が個体におけるQT間隔を延長し得るか否かを決定する方法であって、QT間隔の延長に対する素因に関連するCERKL遺伝子型が、rs895901で非AT、rs1441162で非AA、rs993650で非CT、rs993648で非AG、rs16867450でAA、rs16867452で非TT、及びrs6433927でCCからなる群から選択される、方法。 - rs895901、rs1441162、rs993650、rs993648、rs16867450、rs16867452、及びrs6433927からなる群から選択された、個体がQT間隔の延長に対する素因を有するか否かを決定するための一塩基多型(SNP)マーカー。
- rs895901、rs1441162、rs993650、rs993648、rs16867450、rs16867452、及びrs6433927からなる群から選択された、少なくとも1つの一塩基多型(SNP)座位における個体の遺伝子型を決定するための1つ又は複数の試薬を含む、個体がQT間隔の延長に対する素因を有するか否かを決定するためのキット。
- rs993648における個体の遺伝子型を決定するための1つ又は複数の試薬を含む、請求項5に記載のキット。
- rs895901、rs1441162、rs993650、rs993648、rs16867450、rs16867452、及びrs6433927からなる群から選択された、1つ又は複数のSNPを含む、CERKL遺伝子の選択された変異体の領域と選択的にハイブリダイズするオリゴヌクレオチドのセットを含む、請求項5に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90873407P | 2007-03-29 | 2007-03-29 | |
US60/908,734 | 2007-03-29 | ||
PCT/US2008/058791 WO2008121899A2 (en) | 2007-03-29 | 2008-03-28 | Method of predicting a predisposition to qt prolongation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010522773A JP2010522773A (ja) | 2010-07-08 |
JP5586094B2 true JP5586094B2 (ja) | 2014-09-10 |
Family
ID=39808881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010501271A Active JP5586094B2 (ja) | 2007-03-29 | 2008-03-28 | Qt延長に対する素因を予測する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9074254B2 (ja) |
EP (1) | EP2134873B1 (ja) |
JP (1) | JP5586094B2 (ja) |
ES (1) | ES2542967T3 (ja) |
WO (1) | WO2008121899A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
CA2698534C (en) | 2007-09-10 | 2018-10-09 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
CN104203240A (zh) | 2012-03-14 | 2014-12-10 | 万达制药公司 | 用于治疗精神疾病的伊潘立酮代谢物 |
CN104862308A (zh) * | 2014-02-26 | 2015-08-26 | 文洁 | 一种用于指导他莫昔芬用药的试剂盒 |
US11554106B2 (en) | 2017-03-07 | 2023-01-17 | Marc Childs | Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
WO1993009276A1 (en) | 1991-11-01 | 1993-05-13 | National-Standard Company | Age resistant solder coatings |
WO1993011266A1 (en) | 1991-12-05 | 1993-06-10 | Sloan-Kettering Institute For Cancer Research | Method for the detection of mutations and monoclonal lineages by analysis of rna conformation polymorphism(s) |
US6548636B2 (en) * | 2000-02-29 | 2003-04-15 | Progenics Pharmaceuticals, Inc. | Sulfated CCR5 peptides for HIV-1 infection |
AU2002244568A1 (en) | 2001-03-14 | 2002-09-24 | Mcgill University | Individualization of therapy with antipsychotics |
DK2305656T3 (da) | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
BR0213958A (pt) | 2001-10-31 | 2004-09-08 | Novartis Ag | Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1 |
WO2003044226A2 (en) | 2001-11-23 | 2003-05-30 | Epigenomics Ag | Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder |
US20040096874A1 (en) | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
US20040091909A1 (en) * | 2002-07-05 | 2004-05-13 | Huang Doug Hui | High throughput cytochrome P450 genotyping |
WO2004058052A2 (en) | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP1647600A3 (en) * | 2004-09-17 | 2006-06-28 | Affymetrix, Inc. (A US Entity) | Methods for identifying biological samples by addition of nucleic acid bar-code tags |
CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
-
2008
- 2008-03-28 US US12/593,419 patent/US9074254B2/en active Active
- 2008-03-28 JP JP2010501271A patent/JP5586094B2/ja active Active
- 2008-03-28 EP EP20080744698 patent/EP2134873B1/en active Active
- 2008-03-28 WO PCT/US2008/058791 patent/WO2008121899A2/en active Application Filing
- 2008-03-28 ES ES08744698.5T patent/ES2542967T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
US20100226858A1 (en) | 2010-09-09 |
US9074254B2 (en) | 2015-07-07 |
WO2008121899A2 (en) | 2008-10-09 |
EP2134873A2 (en) | 2009-12-23 |
WO2008121899A3 (en) | 2008-12-31 |
ES2542967T3 (es) | 2015-08-13 |
WO2008121899A8 (en) | 2014-08-21 |
EP2134873B1 (en) | 2015-05-06 |
JP2010522773A (ja) | 2010-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5785697B2 (ja) | Cntf遺伝子多型に基づく、精神病および統合失調症の処置方法 | |
JP5586094B2 (ja) | Qt延長に対する素因を予測する方法 | |
JP5653753B2 (ja) | Snp遺伝子型に基づくqt延長の予測 | |
JP2009541336A (ja) | アルツハイマー病の進行に関するバイオマーカー | |
JP2010538615A (ja) | Snp遺伝子型に基づく抗精神病薬治療 | |
RU2009147281A (ru) | Способы и композиции для диагностики и лечения волчанки | |
MX2014004309A (es) | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. | |
US20180137235A1 (en) | System and method for processing genotype information relating to opioid risk | |
WO2007095580A2 (en) | Treatment response in generalized social phobia | |
JP2016512950A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状(eps)の発症を予測する方法 | |
US10570453B2 (en) | Method of predicting a predisposition to QT prolongation | |
JP2018516231A (ja) | Crhr1拮抗薬を用いた治療に対する反応の遺伝子予測因子を用いた治療の方法 | |
JP5881597B2 (ja) | Qt延長に対する素因を予測する方法 | |
JP5881598B2 (ja) | Abcc2遺伝子の配列又はその産物に基づいてqt延長に対する素因を予測する方法 | |
JP5692872B2 (ja) | Bai遺伝子の配列又はその産物に基づいてqt延長に対する素因を予測する方法 | |
KR20200034125A (ko) | 혈중 스타틴 약물농도 예측을 위한 유전자 마커 | |
JP6474198B2 (ja) | 内臓脂肪蓄積感受性の判定方法 | |
WO2009053513A1 (es) | Procedimiento y kit para la determinación de predisposición, determinación de riesgo a desarrollar o el diagnóstico de psoriasis | |
WO2016176474A1 (en) | System and method for processing genotype information relating to medically-assisted treatment regarding withdrawal or pain | |
EP2787076A1 (en) | Method for evaluating drug sensitivity and susceptibility to diseases by analyzing gene for protein capable of binding to cyclic-amp-responsive sequence | |
JP6596632B2 (ja) | 自閉スペクトラム症への治療効果予測のための検査方法 | |
KR101673156B1 (ko) | 운동 민감도 예측용 바이오마커 | |
JPWO2006068111A1 (ja) | PPARγ遺伝子の遺伝子多型に関連する表現型の判定方法 | |
JP2009219458A (ja) | Ii型糖尿病の検査方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140324 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140624 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140718 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5586094 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |